Allogene Therapeutics Inc. ALLO
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Allogene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer and autoimmune diseases. These 'off-the-shelf' products aim to provide faster, more reliable, and scalable cell therapy options compared…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees150
TickerALLO
Statistics
Market Cap$478.6M
Revenue (TTM)$0
Net Income-$190.9M
Net Margin—
EPS$-0.87
P/E-2.20
P/S—
P/B1.67
EV/EBITDA-2.67
ROE-52.3%
Dividend Yield—
Price$1.96
Data: Twelve Data · Revenue = mcap / P/S